Biogen's tau-lowering diranersen slows Alzheimer's decline 26% at the lowest dose in Phase 2, but an inverse dose response and a missed endpoint cloud the data.
AAIC in London (Ryan Cross for Endpoints News)
July 14, 2026 09:15 AM EDTUpdated 11:22 AM
Questions linger over Biogen's tau drug for Alzheimer's, as low dose reports better results
LONDON — Biogen’s attempt to treat Alzheimer’s by going after a protein that forms toxic tangles in the brain showed some of the strongest proof yet …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
New experimental Alzheimer's drug shows potential after study shows slower cognitive decline | Fortune
Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows
Experimental Alzheimer's drug shows some promise as researchers hunt new approaches
An experimental Alzheimer’s drug shows some promise as researchers hunt new approaches
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Pharmalittle: We're reading about a Biogen Alzheimer's drug, skyrocketing 340B drug sales, and more
Novel Alzheimer's Drug Targeting Tau Shows Promise in Mid-Stage Trial
New experimental drug shows promise in slowing early Alzheimer’s
Why Is Biogen Stock Falling Tuesday? - Biogen (NASDAQ:BIIB)
Biogen's diranersen Phase 2 study showed tau reduction in Alzheimer's but confused experts: The lowest doses had the best…
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher…
A study on Biogen's diranersen found it slowed cognitive decline and has promise in treating Alzheimer's disease, researchers…
